NeuBase Therapeutics is a biopharmaceutical company that aims to help patients with rare genetic diseases and cancers caused by mutant genes. Through its PATrOL platform, the company focuses on developing therapies for genetic disorders, cancer, and oncology. It has lead programs that specifically target Huntington's disease, myotonic dystrophy, and the mutated KRAS gene.